The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | 76-month follow-up data from the CEPHEUS trial: Dara-VRd in newly diagnosed myeloma
Saad Usmani, MD, MBA, FRCP, FASCO, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the 76-month follow-up data from the Phase III CEPHEUS trial (NCT03652064), which evaluated the efficacy of daratumumab in combination with bortezomib, lenolidomide, and dexamethasone (Dara-VRd) in transplant-ineligible patients with newly diagnosed multiple myeloma (MM). This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
